Biochemistry Department-Faculdade de Medicina do ABC, Santo André, Brazil.
Diagn Pathol. 2012 Aug 13;7:97. doi: 10.1186/1746-1596-7-97.
To distinguish between malignant and benign lesions of the thyroid gland histological demonstration is often required since the fine-needle aspiration biopsy method applied pre-operatively has some limitations. In an attempt to improve diagnostic accuracy, markers using immunocytochemistry and immunohistochemistry techniques have been studied, mainly cytokeratin-19 (CK-19), galectin-3 (Gal-3) and Hector Battifora mesothelial-1 (HBME-1). However, current results remain controversial. The aim of the present article was to establish the diagnostic accuracy of CK-19, Gal-3 and HBME-1 markers, as well as their associations, in the differentiation of malignant and benign thyroid lesions.
A systematic review of published articles on MEDLINE and The Cochrane Library was performed. After establishing inclusion and exclusion criteria, 66 articles were selected. The technique of meta-analysis of diagnostic accuracy was employed and global values of sensitivity, specificity, area under the summary ROC curve, and diagnostic odds ratio (dOR) were calculated.
For the immunohistochemistry technique, the positivity of CK-19 for the diagnosis of malignant thyroid lesions demonstrated global sensitivity of 81% and specificity of 73%; for Gal-3, sensitivity of 82% and specificity of 81%; and for HBME-1, sensitivity of 77% and specificity of 83%. The association of the three markers determined sensitivity of 85%, specificity of 97%, and diagnostic odds ratio of 95.1. Similar results were also found for the immunocytochemistry assay.
This meta-analysis demonstrated that the three immunomarkers studied are accurate in pre- and postoperative diagnosis of benign and malignant thyroid lesions. Nevertheless, the search for other molecular markers must continue in order to enhance this diagnostic accuracy since the results found still show a persistency of false-negative and false-positive tests.
Http://www.diagnosticpathology.diagnomx.eu/vs/3436263067345159.
为了区分甲状腺良恶性病变,通常需要组织学表现,因为术前应用的细针抽吸活检方法存在一些局限性。为了提高诊断准确性,已经研究了使用免疫细胞化学和免疫组织化学技术的标志物,主要是细胞角蛋白-19(CK-19)、半乳糖凝集素-3(Gal-3)和 Hector Battifora 间皮素-1(HBME-1)。然而,目前的结果仍存在争议。本文旨在确定 CK-19、Gal-3 和 HBME-1 标志物在鉴别甲状腺良恶性病变中的诊断准确性及其相关性。
对 MEDLINE 和 The Cochrane Library 上发表的文章进行系统综述。在确定纳入和排除标准后,选择了 66 篇文章。采用诊断准确性的荟萃分析技术,计算了敏感性、特异性、汇总 ROC 曲线下面积和诊断比值比(dOR)的全球值。
对于免疫组织化学技术,CK-19 对恶性甲状腺病变的阳性诊断显示出 81%的总体敏感性和 73%的特异性;Gal-3 的敏感性为 82%,特异性为 81%;HBME-1 的敏感性为 77%,特异性为 83%。三种标志物的联合应用确定了 85%的敏感性、97%的特异性和 95.1 的诊断比值比。免疫细胞化学检测也得到了类似的结果。
这项荟萃分析表明,研究的三种免疫标志物在术前和术后诊断甲状腺良恶性病变中是准确的。然而,为了提高这种诊断准确性,必须继续寻找其他分子标志物,因为发现的结果仍然存在假阴性和假阳性试验的持续存在。
Http://www.diagnosticpathology.diagnomx.eu/vs/3436263067345159.